Back
Results - Announcements
Sun Pharma Advanced Research Company Ltd consolidated sales up 202.42% on year in Q2FY2026
10-Aug-2026, 03:44
Sun Pharma Advanced Research Company Ltd share price softened by 2.03% to Rs 212.85 after the company's net profit witnessed a sharp fall of 101.18% to Rs 20.78 crore, while revenue from operations gained significantly 202.42% to Rs 39.92 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.54 lakh crore, rising 5.16%. It has inched up 0.74% over last one week and advanced by 13.39% in last one month while the market capitalization of Sun Pharma Advanced Research Company Ltd has marginally improved by 2.28% and 27.61% in the same period respectively. Profit before tax (PBT) of Sun Pharma Advanced Research Company Ltd stood at Rs 20.67 crore in Q2 FY26, crashing by 60.10% year-on-year, and tumbling by 101.17% quarter-on-quarter. EBITDA came in at Rs 58 crore, declining 5.82% YoY and plunging by 103.26% sequentially. Total expenses marginally dropped 7.64% to Rs 76.12 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 7.66 crore, soaring by 48.45% YoY, while employee benefits expense was at Rs 29.61 crore, soaring 13.80% YoY. For the TTM ended FY26, revenue from operations sank 45.45% to Rs 39.15 crore, while net profit tumbled by 553.48% to Rs 1553.2 crore, compared to previous TTM. EBITDA saw a sharp decline of 32811% to Rs 1587.81 crore, and PBT plunged by 553.06% to Rs 1553.01 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 238.77 crore in FY26, as against Rs 360.29 crore in FY25. Sun Pharma Advanced Research Company Ltd rallied 45.64% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.63% during the same period.
Sun Pharma Advanced Research Company Ltd share price softened by 2.03% to Rs 212.85 after the company's net profit witnessed a sharp fall of 101.18% to Rs 20.78 crore, while revenue from operations gained significantly 202.42% to Rs 39.92 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.54 lakh crore, rising 5.16%. It has inched up 0.74% over last one week and advanced by 13.39% in last one month while the market capitalization of Sun Pharma Advanced Research Company Ltd has marginally improved by 2.28% and 27.61% in the same period respectively. Profit before tax (PBT) of Sun Pharma Advanced Research Company Ltd stood at Rs 20.67 crore in Q2 FY26, crashing by 60.10% year-on-year, and tumbling by 101.17% quarter-on-quarter. EBITDA came in at Rs 58 crore, declining 5.82% YoY and plunging by 103.26% sequentially. Total expenses marginally dropped 7.64% to Rs 76.12 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 7.66 crore, soaring by 48.45% YoY, while employee benefits expense was at Rs 29.61 crore, soaring 13.80% YoY. For the TTM ended FY26, revenue from operations sank 45.45% to Rs 39.15 crore, while net profit tumbled by 553.48% to Rs 1553.2 crore, compared to previous TTM. EBITDA saw a sharp decline of 32811% to Rs 1587.81 crore, and PBT plunged by 553.06% to Rs 1553.01 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 238.77 crore in FY26, as against Rs 360.29 crore in FY25. Sun Pharma Advanced Research Company Ltd rallied 45.64% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.63% during the same period.